GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
The biopharmaceutical company will highlight its advancements in liver diseases, including key assets in ACLF, MASH, and PBC, at the upcoming congress
On May 25, 2026, the biopharmaceutical company GENFIT announced its broad scientific and strategic participation at the upcoming EASL Congress 2026. Operating out of Lille, France, Cambridge, Massachusetts, and Zurich, Switzerland, GENFIT is dedicated to developing therapeutic solutions to improve the lives of patients who are affected by rare and life-threatening liver diseases.[1][2]
GENFIT's scheduled visibility at the congress reflects both its current scientific momentum and its active involvement in the Acute on-Chronic Liver Failure (ACLF) ecosystem. Furthermore, the company's presence highlights its position at an inflection point in MASH, while also drawing attention to the continuous progress being made in Primary Biliary Cholangitis (PBC) through its partnership with Ipsen.[1][2]
As part of its scientific contribution to the EASL Congress, GENFIT has had seven posters accepted for presentation. These accepted posters will primarily cover the company's key assets positioned in ACLF. Additionally, the presentations will feature GENFIT's latest research and work regarding real-world data in the ACLF clinical space.[2]
